2014 TCTAP

Wrap-Up Interview

Antithrombotic Therapies

Moderator

David J. Cohen

Interviewees

Jean-Philippe Collet, Neal S. Kleiman, Manesh Patel

Issues in Briefs

DAPT after DES Implantation

1. Guideline Today
   - ACCF/AHA, ESC
2. Clinical Studies
   - DES Late, OPTIMIZE, PARIS & DAPT trial
   - Discussion

Anticogulants in ACS

1. Guideline Today
   - ACCF/AHA, ESC
2. Clinical studies
   - TAO and EUROMAX trial
   - Discussion

Duration of Dual Anti-platelet Therapy after DES Placement

- **2011 ACCF/AHA/SCAI Guideline**
  - **At least 12 months after DES**
    if patients are not at high risk of bleeding
- **2010 ESC/EACTS Guideline**
  - **6 to 12 months after DES in all patients**
  - **12 months in all patients after ACS**

DES LATE Trial

5,045 DES pts free of MACE, major bleeding on DAPT for at least 12M

Primary endpoint: Cardiac death/MI/stroke at 2 year



Circulation 2014;129:304-312

OPTIMIZE Trial

3,120 patients undergoing endeavor stent implantation

Primary endpoint: death/MI/stroke/major bleeding



JAMA 2013;310:2510-22

PARIS Registry

5,031 patients with stenting enrolled at 15 sites in the US and Europe

***MACE: cardiac death, def/prob ST, spontaneous MI, clinically driven TLR**



Lancet 2013; 382: 1714–22

DAPT Trial

Enrollment completed in July 1, 2011

Results (12 versus 30 months) will be available in late 2014



Discussion

- **Duration of DAPT after DES**
  - **Recent trials: <12 months**
  - **Ongoing trial: DAPT trial (12 vs. 30 months)**
  - **Interpretation: New generation DES**

- **Anticoagulants in ACS**
  - **TAO trial: disappointing results**
  - **EUROMAX trial: promising results**
  - **Interpretation**

Anticoagulants
In Acute Coronary Syndrome

- **ACCF/AHA Guideline**
  - **NSTE-ACS: UFH, enoxaparin or fondaparinux**
  - **STEMI: UFH or bivalirudin**

- **ESC Guideline**
  - **NSTE-ACS: fondaparinux > enoxaparin> UFH**
  - **STEMI: UFH or bivalirudin**

Anti-Xa Agent

OASIS-5 Trial

20,078 patients with NSTE-ACS: fondaparinux vs enoxaparin

Primary endpoint: death/MI/refractory ischemia through 9 days

Death/MI/refractory ischemia



Major bleeding



NEJM 2006;354:1464

Anti-Xa Agent

TAO Trial

13,229 NSTE-ACS patients with a planned early invasive strategy

Primary endpoint: death or MI through 7 days

Death or MI



TIMI major or minor bleeding



JAMA 2013;310:1145-55

EUROMAX Trial

2,218 STEMI patients transported for primary PCI

Primary endpoint: death or major bleeding at 30 days



NEJM 2013;369:2207-17

Discussion

- **Duration of DAPT after DES**
  - **Recent trials: <12 months**
  - **Ongoing trial: DAPT trial (12 vs. 30 months)**
  - **Interpretation: New generation DES**

- **Anticoagulants in ACS**
  - **TAO trial: disappointing results**
  - **EUROMAX trial: promising results**
  - **Interpretation**